ORASURE TECHNOLOGIES INC (OSUR)
Health Care · In vitro diagnostic tests and specimen collection devices · NASDAQ
OrasuRe is a diagnostic company specializing in rapid point-of-care and self-test solutions for infectious diseases and rare conditions, with recent expansion into sickle cell screening through the BioMedomics acquisition.
What ORASURE TECHNOLOGIES INC does
OrasuRe Technologies develops, manufactures, and distributes rapid diagnostic tests and specimen collection devices for infectious diseases, including HIV, Hepatitis C, syphilis, sickle cell disease, and COVID-19, sold to clinical laboratories, hospitals, clinics, and government agencies globally. The company also provides sample management solutions and services used by clinical laboratories, direct-to-consumer labs, pharmaceutical companies, and researchers. It recently acquired BioMedomics to add the SickleSCAN rapid point-of-care test for sickle cell disease to its portfolio.
Themes: ["Rapid point-of-care diagnostics","HIV/AIDS testing","Infectious disease diagnostics","Specimen collection and sample management","Decentralized diagnostics","OTC self-test diagnostics","Sickle cell disease diagnostics"]
Fundamentals
- Price$4.29 as of 2026-07-09 close
- Market cap$296M as of 2026-07-10
- 1-year return+41.4% as of 2026-07-09 close
- Net margin-66.4% as of 2026-07-10
- Gross margin+42.5% as of 2026-07-10
- ROE-21.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-30.1% as of 2026-07-10
- Revenue CAGR (3y)-33.3% SEC XBRL
- Beta1.02 as of 2026-07-10
Key risks (from latest filing)
["Significant revenue decline (-30% YoY) with continued operating losses and negative net margin (-66%), indicating struggled commercialization or market contraction","R&D expenses increased substantially YoY (42% in Q1 2026 vs Q1 2025) while revenues declined, signaling investment burden without proportional near-term returns","Recent acquisition of BioMedomics with contingent consideration liabilities ($27.8M combined current and noncurrent) creates future payment obligations dependent on performance milestones"]
Competitors & peers
- Abbott Diagnostics
- Roche Diagnostics
- Becton Dickinson (BD)
- Bio-Rad Laboratories
- Trinity Biotech
- Chembio Diagnostics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.